Skip to main content

Advertisement

SpringerLink
Log in

GATA2 promotes glioma progression through EGFR/ERK/Elk-1 pathway

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Among the gliomas, glioblastoma (GBM) is the highest grade and the most malignant glioma tumor. GATA2 is a hematopoietic factor that has been intensely studied in hematopoietic malignancies. Recently, the functions of GATA2 as an oncogene in other types of human cancer have been reported. However, no role for GATA2 in the development and progression of glioma has been reported to date. In the present study, we found that the expression level of GATA2 is upregulated in GBM and is correlated with GBM outcome. Ectopic expression of GATA2 or RNAi-mediated knockdown of GATA2 significantly enhanced or inhibited proliferation, migration and invasion of glioma cells. Moreover, we found that epidermal growth factor receptor and extracellular signal-regulated kinase, as upstream components of the signaling pathway, upregulate GATA2 expression; moreover, GATA2 promotes Elk-1 expression. Therefore, a genetic approach or pharmacological intervention targeting GATA2 could potentially serve as an effective strategy for treating glioma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Ahluwalia MS, Chang SM. Medical therapy of gliomas. J Neurooncol. 2014;119:503–12.

    Article  CAS  PubMed  Google Scholar 

  2. Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, Cotzia P, Hooper DC. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 2013;19:3776–86.

    Article  CAS  PubMed  Google Scholar 

  3. Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev. 2014;23:1985–96.

    Article  CAS  Google Scholar 

  4. Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol. 2007;83:91–3.

    Article  CAS  PubMed  Google Scholar 

  5. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG 2nd, Aldape K. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001;61:1122–8.

    CAS  PubMed  Google Scholar 

  6. Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer. 2010;1:1178–88.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Bresnick EH, Katsumura KR, Lee HY, Johnson KD, Perkins AS. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. Nucleic Acids Res. 2012;40:5819–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Chlon TM, Crispino JD. Combinatorial regulation of tissue specification by GATA and FOG factors. Development. 2012;139:3905–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Vicente C, Conchillo A, García-Sánchez MA, Odero MD. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol. 2012;82:1–17.

    Article  PubMed  Google Scholar 

  10. Wang Y, He X, Ngeow J, Eng C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet. 2012;21:569–76.

    Article  CAS  PubMed  Google Scholar 

  11. Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A, Downward J. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 2012;149:642–55.

    Article  CAS  PubMed  Google Scholar 

  12. Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget. 2014;5:451–61.

    PubMed Central  PubMed  Google Scholar 

  13. Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res. 2009;15:460–7.

    Article  CAS  PubMed  Google Scholar 

  14. Liu KJ, Chen CT, Hu WS, Hung YM, Hsu CY, Chuang BF, Juang SH. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme. Int J Oncol. 2004;24:581–90.

    PubMed  Google Scholar 

  15. Carlsson J, Ren ZP, Wester K, Sundberg AL, Heldin NE, Hesselager G, Persson M, Gedda L, Tolmachev V, Lundqvist H, Blomquist E, Nistér M. Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. J Neurooncol. 2006;77:33–45.

    Article  CAS  PubMed  Google Scholar 

  16. Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene. 2006;25:278–87.

    PubMed  Google Scholar 

  17. Mut M, Lule S, Demir O, Kurnaz IA, Vural I. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3 K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells. Int J Biochem Cell Biol. 2012;44:302–10.

    Article  CAS  PubMed  Google Scholar 

  18. Wu P, Wee P, Jiang J, Chen X, Wang Z. Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation. PLoS ONE. 2012;7:e41354.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Menon LG, Pratt J, Yang HW, Black PM, Sorensen GA, Carroll RS. Imaging of human mesenchymal stromal cells: homing to human brain tumors. J Neurooncol. 2012;107:257–67.

    Article  PubMed  Google Scholar 

  20. Terasaki M, Sugita Y, Arakawa F, Okada Y, Ohshima K, Shigemori M. CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathol. 2011;28:89–97.

    Article  CAS  PubMed  Google Scholar 

  21. Broniscer A, Baker SJ, Stewart CF, Merchant TE, Laningham FH, Schaiquevich P, Kocak M, Morris EB, Endersby R, Ellison DW, Gajjar A. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res. 2009;15:701–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61:2965–78.

    Article  PubMed  Google Scholar 

  23. Adachi T, Kar S, Wang M, Carr BI. Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J Cell Physiol. 2002;192:151–9.

    Article  CAS  PubMed  Google Scholar 

  24. Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, Finocchiaro G, Sanson M. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83:1200–6.

    Article  PubMed  Google Scholar 

  25. Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012;12:197–209.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Moriguchi T, Yamamoto M. A regulatory network governing Gata1 and Gata2 gene transcription orchestrates erythroid lineage differentiation. Int J Hematol. 2014;100:417–24.

    Article  CAS  PubMed  Google Scholar 

  27. Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer. 2012;11:84.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by University Graduate Students’ Scientific Research Innovative Program of Jiangsu Province, China (CXLX12-0843); National Natural Science Foundation of China (81172400, 81272799 and 81472739); Scientific and Technological Development Program of Suzhou, China (SYS201477, SYSD2012090); and Priority Academic Program Development of Jiangsu Higher Education Institutions, China.

Conflict of interest

None.

Author information

Author notes

    Authors and Affiliations

    1. Department of Neurosurgery, Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China

      Zhongyong Wang, Chao Sun, Liang Xu, Yanming Chen, Qing Zhu, Qiang Huang, Jun Dong & Qing Lan

    2. Department of Otorhinolaryngology, Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China

      Hui Yuan

    3. Department of Pathology, Second Affiliated Hospital of Soochow University, 1055 Sanxiang Road, Suzhou, 215004, China

      Haifeng Zhao

    Authors
    1. Zhongyong Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Hui Yuan
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Chao Sun
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Liang Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Yanming Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Qing Zhu
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Haifeng Zhao
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Qiang Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Jun Dong
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Qing Lan
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Jun Dong or Qing Lan.

    Additional information

    Zhongyong Wang, Hui Yuan and Chao Sun have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Wang, Z., Yuan, H., Sun, C. et al. GATA2 promotes glioma progression through EGFR/ERK/Elk-1 pathway. Med Oncol 32, 87 (2015). https://doi.org/10.1007/s12032-015-0522-1

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1007/s12032-015-0522-1

    Keywords

    Search

    Navigation